KR20220044739A - 국소 조성물 - Google Patents

국소 조성물 Download PDF

Info

Publication number
KR20220044739A
KR20220044739A KR1020227004324A KR20227004324A KR20220044739A KR 20220044739 A KR20220044739 A KR 20220044739A KR 1020227004324 A KR1020227004324 A KR 1020227004324A KR 20227004324 A KR20227004324 A KR 20227004324A KR 20220044739 A KR20220044739 A KR 20220044739A
Authority
KR
South Korea
Prior art keywords
composition
latanoprost
use according
subfluorinated
alkane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227004324A
Other languages
English (en)
Korean (ko)
Inventor
프랑크 로쉐
베른하드 하웁트메이어
Original Assignee
노바리크 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노바리크 게엠베하 filed Critical 노바리크 게엠베하
Priority to KR1020267011694A priority Critical patent/KR20260055529A/ko
Publication of KR20220044739A publication Critical patent/KR20220044739A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227004324A 2019-08-09 2020-08-06 국소 조성물 Ceased KR20220044739A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020267011694A KR20260055529A (ko) 2019-08-09 2020-08-06 국소 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19191035.5 2019-08-09
EP19191035 2019-08-09
PCT/EP2020/072211 WO2021028328A1 (en) 2019-08-09 2020-08-06 Topical composition comprising a prostaglandin analogue

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267011694A Division KR20260055529A (ko) 2019-08-09 2020-08-06 국소 조성물

Publications (1)

Publication Number Publication Date
KR20220044739A true KR20220044739A (ko) 2022-04-11

Family

ID=67587648

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227004324A Ceased KR20220044739A (ko) 2019-08-09 2020-08-06 국소 조성물
KR1020267011694A Pending KR20260055529A (ko) 2019-08-09 2020-08-06 국소 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020267011694A Pending KR20260055529A (ko) 2019-08-09 2020-08-06 국소 조성물

Country Status (8)

Country Link
US (2) US20220362382A1 (cg-RX-API-DMAC10.html)
EP (1) EP4009952A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022543402A (cg-RX-API-DMAC10.html)
KR (2) KR20220044739A (cg-RX-API-DMAC10.html)
CN (1) CN114206344A (cg-RX-API-DMAC10.html)
AU (2) AU2020330424A1 (cg-RX-API-DMAC10.html)
CA (1) CA3144193A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021028328A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6039145B2 (ja) 2011-05-25 2016-12-07 ノバリック ゲーエムベーハー 半フッ化アルカンを基礎にした局所薬学的組成物
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
MX381639B (es) 2016-12-23 2025-03-13 Novaliq Gmbh Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
AU2019246035B2 (en) 2018-03-28 2024-07-18 Novaliq Gmbh Pharmaceutical composition comprising timolol
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
CN114449999A (zh) 2019-09-06 2022-05-06 诺瓦利克有限责任公司 用于治疗葡萄膜炎的眼用组合物
IL330080A (en) 2023-12-19 2026-08-01 Glenmark Specialty S A A preparation for external use containing dutasteride and lanotrost for the treatment of alopecia
AU2025207999A1 (en) * 2024-01-11 2026-07-23 Glenmark Specialty S.A. Topical composition comprising clascoterone and latanoprost for alopecia
WO2026013128A1 (en) * 2024-07-10 2026-01-15 Dermaliq Therapeutics, Inc. Treatment of androgenetic alopecia
WO2026104414A1 (en) * 2024-11-12 2026-05-21 Dermaliq Therapeutics Gmbh Topical compositions for the treatment of alopecia areata

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69823852T2 (de) 1997-02-04 2005-05-19 Johnstone, Murray A., Seattle Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
JP2005225817A (ja) * 2004-02-13 2005-08-25 Jiyugaoka Clinic 睫毛用育毛剤
US9149484B2 (en) * 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
NZ716349A (en) * 2009-11-09 2017-07-28 Allergan Inc Compositions and methods for stimulating hair growth
ES2564502T3 (es) * 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
CN103561724B (zh) * 2011-05-25 2016-06-29 诺瓦利克有限责任公司 给药给甲的药物组合物
AU2013208002B2 (en) 2012-01-10 2017-11-30 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
EP2944324A1 (de) * 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
DK3442480T3 (da) * 2016-06-23 2020-01-13 Novaliq Gmbh Fremgangsmåde til topisk indgivelse
JP7814839B2 (ja) * 2017-09-27 2026-02-17 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物

Also Published As

Publication number Publication date
AU2026202586A1 (en) 2026-04-23
JP2022543402A (ja) 2022-10-12
CN114206344A (zh) 2022-03-18
WO2021028328A1 (en) 2021-02-18
AU2020330424A1 (en) 2022-03-03
CA3144193A1 (en) 2021-02-18
EP4009952A1 (en) 2022-06-15
US20220362382A1 (en) 2022-11-17
JP2025160428A (ja) 2025-10-22
KR20260055529A (ko) 2026-04-23
US20260041773A1 (en) 2026-02-12

Similar Documents

Publication Publication Date Title
US20260041773A1 (en) Topical composition comprising a prostaglandin analogue
RU2567792C2 (ru) Композиции и способы стимулирования роста волос
EP2640350B1 (en) Compositions and methods for hair growth
US9149484B2 (en) Compositions and methods for stimulating hair growth
JP6082158B2 (ja) ビマトプロストを含む局所用組成物及びそれを用いた育毛の刺激方法
EP3886799B1 (en) Compositions for the treatment of hair loss
US20190060288A1 (en) Topical compoisition comprising tacrolimus
US20150165002A1 (en) Exfoliative hair retention-promoting formulation
CA2784542C (fr) Utilisation du 2,3-dihydroxypropyl dodecanoate pour le traitement de la seborrhee
ES2313124T3 (es) Reduccion del crecimiento capilar aplicando un agonista del receptor de prostagladina.
US20250325545A1 (en) Methods and compositions for the treatment of hair loss
JP2026513803A (ja) 脱毛の治療において使用するためのクラスコテロンとミノキシジルとの併用治療
CA3193642A1 (en) Compositions and methods for the treatment of hair loss and other conditions
CN101087583A (zh) 用生存素抑制剂来减少毛发生长
CN114025768A (zh) 促进毛发生长的药品
WO2026013128A1 (en) Treatment of androgenetic alopecia
UA118835C2 (uk) Композиція і спосіб стимулювання росту волосся
HK1188740A (en) Compositions and methods for hair growth
HK1188740B (en) Compositions and methods for hair growth

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601